184 related articles for article (PubMed ID: 35918045)
1. Rabphilin-3A as a novel target to reverse α-synuclein-induced synaptic loss in Parkinson's disease.
Ferrari E; Scheggia D; Zianni E; Italia M; Brumana M; Palazzolo L; Parravicini C; Pilotto A; Padovani A; Marcello E; Eberini I; Calabresi P; Diluca M; Gardoni F
Pharmacol Res; 2022 Sep; 183():106375. PubMed ID: 35918045
[TBL] [Abstract][Full Text] [Related]
2. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Stanic J; Mellone M; Napolitano F; Racca C; Zianni E; Minocci D; Ghiglieri V; Thiolat ML; Li Q; Longhi A; De Rosa A; Picconi B; Bezard E; Calabresi P; Di Luca M; Usiello A; Gardoni F
Neurobiol Dis; 2017 Dec; 108():54-64. PubMed ID: 28823933
[TBL] [Abstract][Full Text] [Related]
3. Rabphilin 3A retains NMDA receptors at synaptic sites through interaction with GluN2A/PSD-95 complex.
Stanic J; Carta M; Eberini I; Pelucchi S; Marcello E; Genazzani AA; Racca C; Mulle C; Di Luca M; Gardoni F
Nat Commun; 2015 Dec; 6():10181. PubMed ID: 26679993
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein Oligomers Induce Glutamate Release from Astrocytes and Excessive Extrasynaptic NMDAR Activity in Neurons, Thus Contributing to Synapse Loss.
Trudler D; Sanz-Blasco S; Eisele YS; Ghatak S; Bodhinathan K; Akhtar MW; Lynch WP; Piña-Crespo JC; Talantova M; Kelly JW; Lipton SA
J Neurosci; 2021 Mar; 41(10):2264-2273. PubMed ID: 33483428
[TBL] [Abstract][Full Text] [Related]
5. Rabphilin-3A Drives Structural Modifications of Dendritic Spines Induced by Long-Term Potentiation.
Franchini L; Stanic J; Barzasi M; Zianni E; Mauceri D; Diluca M; Gardoni F
Cells; 2022 May; 11(10):. PubMed ID: 35626653
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein (αSyn) Preformed Fibrils Induce Endogenous αSyn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons.
Wu Q; Takano H; Riddle DM; Trojanowski JQ; Coulter DA; Lee VM
J Neurosci; 2019 Jun; 39(26):5080-5094. PubMed ID: 31036761
[TBL] [Abstract][Full Text] [Related]
7. Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala.
Chen L; Nagaraja C; Daniels S; Fisk ZA; Dvorak R; Meyerdirk L; Steiner JA; Escobar Galvis ML; Henderson MX; Rousseaux MWC; Brundin P; Chu HY
Elife; 2022 Jul; 11():. PubMed ID: 35775627
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
9. Rabphilin-3A undergoes phase separation to regulate GluN2A mobility and surface clustering.
Yang L; Wei M; Wang Y; Zhang J; Liu S; Liu M; Wang S; Li K; Dong Z; Zhang C
Nat Commun; 2023 Jan; 14(1):379. PubMed ID: 36693856
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism.
Choong CJ; Aguirre C; Kakuda K; Beck G; Nakanishi H; Kimura Y; Shimma S; Nabekura K; Hideshima M; Doi J; Yamaguchi K; Nakajima K; Wadayama T; Hayakawa H; Baba K; Ogawa K; Takeuchi T; Badawy SMM; Murayama S; Nagano S; Goto Y; Miyanoiri Y; Nagai Y; Mochizuki H; Ikenaka K
Acta Neuropathol; 2023 May; 145(5):573-595. PubMed ID: 36939875
[TBL] [Abstract][Full Text] [Related]
11. Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.
Pathak D; Berthet A; Bendor JT; Yu K; Sellnow RC; Orr AL; Nguyen MK; Edwards RH; Manfredsson FP; Nakamura K
eNeuro; 2017; 4(2):. PubMed ID: 28462393
[TBL] [Abstract][Full Text] [Related]
12. Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits.
Negrini M; Tomasello G; Davidsson M; Fenyi A; Adant C; Hauser S; Espa E; Gubinelli F; Manfredsson FP; Melki R; Heuer A
J Parkinsons Dis; 2022; 12(4):1133-1153. PubMed ID: 35213388
[TBL] [Abstract][Full Text] [Related]
13. Synaptic dysfunction in Parkinson's disease.
Picconi B; Piccoli G; Calabresi P
Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein decoy peptide protects mice against α-synuclein-induced memory loss.
Guo Q; Kawahata I; Jia W; Wang H; Cheng A; Yabuki Y; Shioda N; Fukunaga K
CNS Neurosci Ther; 2023 Jun; 29(6):1547-1560. PubMed ID: 36786129
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.
Diepenbroek M; Casadei N; Esmer H; Saido TC; Takano J; Kahle PJ; Nixon RA; Rao MV; Melki R; Pieri L; Helling S; Marcus K; Krueger R; Masliah E; Riess O; Nuber S
Hum Mol Genet; 2014 Aug; 23(15):3975-89. PubMed ID: 24619358
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.
Durante V; de Iure A; Loffredo V; Vaikath N; De Risi M; Paciotti S; Quiroga-Varela A; Chiasserini D; Mellone M; Mazzocchetti P; Calabrese V; Campanelli F; Mechelli A; Di Filippo M; Ghiglieri V; Picconi B; El-Agnaf OM; De Leonibus E; Gardoni F; Tozzi A; Calabresi P
Brain; 2019 May; 142(5):1365-1385. PubMed ID: 30927362
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
18. Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species.
Carta AR; Boi L; Pisanu A; Palmas MF; Carboni E; De Simone A
J Neurosci Methods; 2020 May; 338():108685. PubMed ID: 32173400
[TBL] [Abstract][Full Text] [Related]
19. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.
Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y
PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway.
Park JH; Burgess JD; Faroqi AH; DeMeo NN; Fiesel FC; Springer W; Delenclos M; McLean PJ
Mol Neurodegener; 2020 Jan; 15(1):5. PubMed ID: 31931835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
